Table 1 Clinicopathological features of patients with NSCLC rebiopsied after EGFR TKI resistance acquisition
No. of cases | 123 |
|---|---|
baseline morphology | NSCLC 100% |
EGFR TKI | |
afatinib | 55 |
gefitinib | 35 |
erlotinib | 33 |
median age (range) | 68 (40–87) |
< 65 years (%) | 24 |
> 65 years (%) | 76 |
sex (%) | |
male | 53 |
female | 70 |
primary EGFR mutation | |
EGFR exon 19 deletion | 89 |
EGFR exon 21 p.L858R | 33 |
EGFR exon 19 duplication | 1 |